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Heart Failure and Chronic Obstructive Pulmonary Disease
The Quandary of Beta-Blockers and Beta-Agonists
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The combination of heart failure and chronic obstructive pulmonary disease presents many therapeutic chal-
lenges. The cornerstones of therapy are beta-blockers and beta-agonists, respectively. Their pharmacological
effects are diametrically opposed, and each is purported to adversely affect the alternative condition. The tolera-
bility of beta-blockade in patients with mild and fixed airflow obstruction likely extends to those with more se-
vere disease. However, the evidence is rudimentary. The long-term influence of beta-blockade on pulmonary
function, symptoms, and quality of life is unclear. Low-dose initiation and gradual up-titration of cardioselective
beta-blockers is currently recommended. Robust clinical trials are needed to provide the answers that may fi-
nally allay physicians’ mistrust of beta-blockers in patients with chronic obstructive pulmonary disease. Beta-
agonists are associated with incident heart failure in patients with pulmonary disease and with increased mor-
tality and hospitalization in those with existing heart failure. These purported adverse effects require further
investigation. In the meantime, clinicians should consider carefully the etiology of dyspnea and obtain objective
evidence of airflow obstruction before prescribing beta-agonists to patients with heart failure. (J Am Coll
Cardiol 2011;57:2127–38) © 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.020i
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mHeart failure (HF) and chronic obstructive pulmonary
disease (COPD) are global epidemics affecting in excess of
10 million patients (1,2). The cornerstones of therapy are
beta-blockers and beta-agonists, respectively. The short-
and long-term effects of beta-blockade are diametrically
opposed: Acute negative inotropy precedes improved left
ventricular systolic function. Beta-blockers confer protec-
tion from chronically elevated catecholamines and lead to
up-regulation of beta-receptors. Reverse remodeling occurs.
Beta-agonists exert the reverse pharmacological effects of
beta-blockers. Exposure induces down-regulation and de-
sensitization of beta-receptors (3). However, whether acute
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2011, accepted February 22, 2011.positive inotropy gives way to longer term left ventricular
systolic dysfunction (LVSD) is uncertain.
Although one-third of patients with HF have concurrent
COPD (4), few reports have addressed the simple thera-
peutic questions that interest physicians. Does “severe” or
“reversible” airflow obstruction preclude beta1-selective
blockade? Is bronchoconstriction lessened by using a beta-
blocker with alpha1-antagonist activity? Do beta-blockers
mprove the prognosis of patients with both conditions?
ow safe are oral and inhaled beta-agonists in patients with
F? Here, we critically appraise the controversial issues of
eta-blockers and beta-agonists in patients with HF and
OPD.
ethods
o examine beta-blockers in COPD, the CENTRAL
Cochrane Central Register of Controlled Trials) was
earched for randomized, controlled, single- or double-
linded trials. Medical subject heading (MeSH) terms “respi-
atory tract diseases” and “adrenergic beta-antagonists” yielded
27 studies, 18 of which addressed the review objectives
5-22). Key word searches “chronic obstructive lung disease”
nd “beta adrenergic receptor blocking agent” or “[beta-blocker
ame]” identified 2 further studies (23,24). These 20 studies
atched the recent Cochrane library systematic review (25).
urther information was gathered searching Medline using
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mans) ”lung diseases, obstructive”
and ”adrenergic beta-antagonists”
(n  576) (26-29).
The relationship between oral
or inhaled beta-agonists and HF
was examined in CENTRAL us-
ing MeSH terms “heart failure”
and “adrenergic beta-agonists”
(n  187). All studies involving
nebulized or inhaled beta-agonists
were included (30-32). Given the
unequivocal results of large ran-
domized controlled trials investi-
gating xamoterol (33,34), we re-
stricted further inclusion of oral
beta-agonists to larger studies lasting at least 1 month (35).
Medline was searched for “heart failure” and “adrenergic
beta-agonists” (n  374) (33–38) or “albuterol” (n  42)
30–32,39,40) or “terbutaline” (n  25) (41) or “pirbuterol”
n  37) (42). Substituting “cardiomyopathy, dilated” for
heart failure” located 2 additional studies (43,44). Com-
ining the remaining beta-agonists in the MeSH hierarchy
dentified no new references.
Finally, Medline was searched using MeSH terms “lung
iseases, obstructive” and “heart failure” (n  969) (45,46).
ibliographies of the Cochrane review and all publications
dentified by the search strategies were systematically re-
iewed (25).
uidelines Regarding Beta-Blocker Use
n Patients With HF and COPD
he American College of Cardiology/American Heart As-
ociation guidelines for the management of HF advocate
great caution” when using beta-blockers in patients with
ymptomatic “reactive airways disease” (47,48). No defini-
ion of “reactive airways disease” is provided. Concerns stem
rom reports of acute bronchospasm in asthmatic patients
iven noncardioselective beta-blockers (49–51). The guide-
lines also state that “most patients” with COPD “remain
reasonable candidates for beta-blockade.” More precise
advice is lacking. By contrast, the European Society of
Cardiology guidelines clearly state that COPD “is not a
Abbreviations
and Acronyms
CI  confidence interval
COPD  chronic
obstructive pulmonary
disease
FEV1  forced expiratory
volume in 1 s
HF  heart failure
LVSD  left ventricular
systolic dysfunction
MeSH  medical subject
heading
OR  odds ratio
Properties of Beta-Blockers Approved for the Treatment of HFTable 1 Properties of Beta-Blockers Approved for the Treatmen
Beta-Blocker
Beta1-Selectivity
(Ref. #)
Alpha-
Antagonism
Carvedilol (53) 1 
Metoprolol tartrate (54) 40 —
Metoprolol succinate (57) 40* —
Bisoprolol (55) 75 —
Nebivolol (56) 300 —
Dashes indicate that the property is not present. *The clinical cardioselectivity of metoprolol succi
even beta-blockade achieved with this formulation avoiding peaks and troughs (57).
HF  heart failure.contraindication” (1). Low-dose initiation and gradual up-
titration is recommended. Furthermore, the guidance indi-
cates, “mild deterioration in pulmonary function and symp-
toms should not lead to prompt discontinuation.”
Properties of Beta-Blockers
Approved for the Treatment of HF
Greater beta1-receptor affinity provides a wider division
etween beta1 and beta2-adrenoceptor blockade, the latter
ediating bronchoconstriction. Estimates of beta1 affinity
(so-called cardioselectivity) vary according to methodology.
In vitro, beta1/beta2 selectivity ratios have been derived from
eceptor binding studies in a wide range of tissues using
ifferent response measures, agonists, and antagonists. Beta1
selectivity is demonstrated in vivo through antagonism of
biochemical and hemodynamic responses to beta2 stimuli
52). Table 1 outlines the properties of beta-blockers ap-
roved for the treatment of HF (53–56). Cardioselectivity is
ose-dependent. Higher plasma concentrations increase
ompetitive antagonism of beta2-adrenoceptors with only
limited incremental beta1-blockade (52,57,58). Beta2-
lockade may increase airflow obstruction in susceptible
atients, possibly through unopposed parasympathetic
ronchoconstriction (59,60).
andomized Trials of Cardioselective
eta-Blockade in COPD
nly 1 small study has prospectively examined beta-
lockade in patients with both HF and COPD (61). The
vidence in those with COPD alone informs our daily
ecisions. Any review of “COPD and HF” must, there-
ore, objectively appraise beta-blockade in “COPD with-
ut HF.” A Cochrane library meta-analysis concluded
hat long-term cardioselective beta-blockade is safe and
ell-tolerated in COPD (25,62). This meta-analysis
valuated pulmonary function in 20 randomized, con-
rolled, crossover trials of cardioselective beta1-blockers
n patients with COPD (Table 2) (5–24). No study
ncluded any patients with HF.
The evidence has many limitations. Only 2 studies
nvolved more than 20 patients (15,23), some were only
ingle-blinded (19,20), and others lacked placebo control
HF
Intrinsic
mpathomimetic
Activity
Lipid
Solubility
Route of
Elimination Half-Life (h)
— Moderate Hepatic 7–10
— Moderate Hepatic 3–7
— Moderate Hepatic 20
— Low Hepatic/Renal 10–12
— High Hepatic 12–19
ntrolled release/extended release is much higher than that of metoprolol tartrate because of thet of
Sy
nate co
Randomized Controlled Trials of Cardioselective Beta-Blockers in Patients With COPDTable 2 Randomized Controlled Trials of Cardioselective Beta-Blockers in Patients With COPD
First Author (Ref. #) n Duration Severe Reversibility
Placebo
Control
Double
Blind
Mean FEV1
(l)
Mean FEV1
(% Predicted)
Beta-
Blocker Route
Dose
(mg)
Reduction FEV1
(l)
Anderson et al. (5) 9 Single dose — — Yes Yes — — Metoprolol PO 100 —
Propranolol 80
Beil and Ulmer (22) 20 Single dose — — Yes Yes — — Atenolol PO 100 —
Propranolol 80
Sorbini et al. (24) 8 Single dose — — — Yes 1.9 — Metoprolol PO 50, 100, 150, 200 10%
Schaanning and Vilsvik (6) 20 Single dose — — Yes Yes 1.9 — Practolol IV 15 6%
Perks et al. (12) 10 Single dose — — Yes Yes 1.9 — Atenolol PO 50, 100 —
Oxprenolol 80
Lammers et al. (7) 8 4 weeks — — Yes Yes 2.4 — Metoprolol PO 100 b.i.d. 0.25
Pindolol 10 b.i.d. 0.20
Tivenius (8) 12 2 days — — Yes Yes 1.7 50 Metoprolol PO 50 t.i.d. 0.14
Propranolol 40 t.i.d. 0.41
van der Woude et al. (21) 15 4 days — — Yes Yes 2.4 72 Propranolol PO 80 0.33
Metoprolol 100 0.25
Celiprolol 200 0.09
Ranchod et al. (9) 15 3 weeks — — Yes Yes 2.3 — Atenolol PO 100 o.d. 0.13
Propranolol 40 q.i.d. 0.12
Adam et al. (10) 10 Single dose — Yes Yes Yes 1.7 — Metoprolol PO 100 0.09
Atenolol 100 0.15
Labetalol 200 0.01
Propranolol 80 0.23
von Wichert (11) 12 Single dose — Yes Yes Yes — — Metoprolol PO 100 —
Pindolol 5
Dorow et al. (13) 12 Single dose — Yes Yes Yes 1.6 — Bisoprolol PO 20 NS
Atenolol 100 NS
Macquin-Mavier et al. (14) 9 Single dose — Yes Yes Yes — 80 Bisoprolol PO 10 —
Acebutolol 400
Dorow et al. (15) 34 12 weeks — Yes — Yes 1.7 — Celiprolol PO 200, 400, 600 NS
McGavin and Williams (16) 9 Single dose Yes — — Yes 1.1 40 Metoprolol PO 100 0.03
Propranolol 80 0.27
Sinclair (17) 10 Single dose Yes — Yes Yes 1.3 — Metoprolol IV 0.12 mg/kg 0.07
Propranolol 0.06 mg/kg 0.20
Wunderlich et al. (23) 35 2 days Yes — Yes Yes 1.3 — Metoprolol PO 100 b.i.d. 16%
Propranolol 80 b.i.d. 36%
Butland et al. (18) 12 4 weeks Yes — Yes Yes — 26 Metoprolol PO 100 o.d. 11%
Atenolol 100 o.d. 10%
Fogari et al. (19) 10 1 week Yes Yes — — 1.3 — Atenolol PO 100 NS
Celiprolol 200 NS
Oxprenolol 80 14%
Propranolol 16%
Fenster et al. (20) 6 1 week Yes Yes Yes — — 45 Metoprolol PO 50 q.i.d. 6%
b.i.d.  twice a day; COPD  chronic obstructive pulmonary disease; FEV1  forced expiratory volume in 1 s; IV  intravenously; NS  not significant; o.d.  once daily; PO  orally; q.i.d.  4 times daily; t.i.d.  3 times daily.
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dose, and only 1 lasted longer than a month (15). The effect
of long-term beta-blockade, therefore, is unknown. The 9
“long-term” studies (defined as more than a single treatment
dose) involved 147 young, predominantly male patients
with moderate airways obstruction (mean forced expiratory
volume in 1 s [FEV1]: 1.8 l). Information is particularly
limited for beta-blockers conferring benefit in HF. Al-
though many trials used metoprolol, only 2 single-dose
studies used bisoprolol (13,14), and none used carvedilol or
nebivolol. Most important of all, the evidence lacks the hard
clinical endpoints that characterize HF trials.
Effect of Cardioselective Beta-Blockade
in COPD With Reversible Airflow Obstruction
Of the 20 trials included in the Cochrane meta-analysis, 7
involved patients with reversible airflow obstruction, defined
by FEV1 improvement 15% following beta2-agonists
10,11,13–15,19,20). Those studies show FEV1 was unaf-
fected by either single dose or longer duration cardioselec-
tive beta-blockade (–1.8% and –1.26%, respectively). How-
ever, the “long-term” data were derived primarily from a
single randomized trial lasting just 12 weeks (15). Celipro-
lol, a rarely used cardioselective beta-blocker with mild
beta2-agonism and alpha2-antagonism, caused no signifi-
ant change in FEV1 in 34 patients with moderate reversible
irflow obstruction.
The longest study to date examining beta-blockade in
OPD contradicts these results, but it was not included in
he meta-analysis. In a randomized, double-blind, crossover
rial (63), 40 patients with mild COPD and significant
eversibility received bisoprolol 5 mg or atenolol 50 mg. In
hat study, FEV1 declined significantly over 6 months by
approximately 0.2 l in both treatment arms. Although
lacking a concurrent placebo group, lung function parame-
ters normalized during the placebo crossover period, sug-
gesting beta-blockade directly caused bronchoconstriction.
The Cochrane meta-analysis also reported no significant
inhibition of beta2-agonist response by cardioselective beta-
lockers. However, of the 4 small studies (10,17,19,21),
nly 2 included patients with significant reversibility
10,19). The minimal influence on bronchodilation is there-
ore unsurprising. Overall, the long-term effect of cardiose-
ective beta-blockers in patients with COPD and significant
eversibility is unknown.
ffect of Cardioselective Beta-Blockade
n Severe Airflow Obstruction
he same caveats apply to the evidence for beta-blockade in
atients with severe COPD. The few existing studies are
mall, of limited duration, predominantly used metoprolol, had
o dose titration, and excluded patients with HF (Table 2).
he Cochrane library separately analyzed 6 trials with mean
aseline FEV1 1.4 l or 50% of normal predicted values(16–20,23). No significant change occurred in FEV1 fol-lowing single-dose or longer-term beta-blocker therapy
(–0.71% and –3.11%, respectively) (25). However, the
“long-term” results were derived from 2 studies that lasted
just 1 week and recruited 16 patients (19,20). Inexplicably,
the presented weighted mean difference (–3.11%) failed to
incorporate 2 of the 6 referenced studies (18,23). In these,
metoprolol reduced FEV1 by 16% in 35 patients, whereas
atenolol and metoprolol each significantly reduced FEV1 by
approximately 10% in 12 patients.
Effect of Cardioselective
Beta-Blockade on Symptoms
Only 1 patient in each of the beta-blocker and placebo
groups experienced increased respiratory symptoms in the
Cochrane meta-analysis (25). The longer duration treat-
ment ranged from just 2 days to 12 weeks. Over short
periods, patients may curtail typical daily activities, thus
underestimating the effect on symptoms. The perception of
respiratory effort and associated distress is subjective and
variable with time, reflecting a complex interaction between
psychology and physiology (64). Quantification based on
physical exertion also fails to reflect mental health and social
functioning (65). Only 1 trial formally assessed the effect of
beta-blockade on dyspnea and health-related quality of life
(61). Over 4 months, bisoprolol titration in 27 patients with
HF and concurrent COPD resulted in a nonsignificant
improvement in dyspnea and health status assessed using
generic and disease-specific questionnaires. These findings
require validation in larger cohorts.
Almost all trials evaluating beta-blockade in HF excluded
patients with significant pulmonary disease, documented
COPD, or bronchodilator therapy (Table 3). The only trial
not specifying pulmonary disease or bronchodilators within
the exclusion criteria was MERIT-HF (Metoprolol CR/XL
Randomized Intervention Trial in Congestive Heart Fail-
ure) (66). Despite this, just 210 (5.3%) of the 3,991 patients
enrolled had documented COPD (personal communica-
tion, J. Wikstrand, October 2009). Even in beta-blocker
trials with less stringent criteria, investigators likely avoid
recruiting patients with airflow obstruction. No trial publi-
cations report bronchospasm. Whether this reflects genuine
tolerability, limited detection strategies, or exclusion of
patients with airflow obstruction is unclear. The incidence
of respiratory adverse events was similar in the metoprolol
and placebo arms of MERIT-HF, including bronchospasm
(respectively, 0.3% vs. 0.4%), exacerbation of COPD or
bronchitis (0.4% vs. 0.4%), and pneumonia (2.0% vs. 1.9%).
Effect of Noncardioselective Beta- and
Alpha-Blockade on Airflow Obstruction
Carvedilol is the only noncardioselective beta-blocker
approved for treating HF. Many trials in the Cochrane
meta-analysis reported adverse side effects with non-
selective beta-blockers. Propranolol significantly reduced
FEV1 (8-10,16,17,19,21,23), antagonized beta-agonists
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necessitated withdrawal of patients from studies (8,9,16,23).
The purported mitigating effect of alpha-blockade is cir-
cumstantial at best. Two retrospective Australian analyses
assessed carvedilol in patients with HF and airflow obstruc-
tion. The first (67) studied 808 consecutive patients com-
mencing open-label treatment, excluding patients with an-
ticipated beta-blocker intolerance. Among 89 patients with
coexistent COPD or asthma, 85% tolerated carvedilol. No
comments were made regarding the severity and reversibility
of airflow obstruction or the reasons for intolerance. The
results undoubtedly reflect selection bias rather than true
tolerability. The second study (27) examined 31 patients
with concomitant moderate COPD without significant
reversibility (mean FEV1: 62% predicted, reversibility: 4%).
Of those patients, 84% tolerated carvedilol, with only 1
patient withdrawing due to wheezing. However, patients
were predominantly young men and only 39% used
inhaled bronchodilators. Applicability to real-world pa-
tients is limited.
Beta-blockers were well tolerated in 124 patients
attending a community HF clinic diagnosed with mod-
erate to severe airflow obstruction using handheld spi-
rometry, over one-half of whom received carvedilol (26).
However, many patients with established airways disease
were excluded, only a minority received bronchodilators,
and the FEV1 in those prescribed carvedilol was not
Exclusion Criteria, Prevalence of COPD, and Respiratory SymptomsTable 3 Exclusion Criteria, Prevalence of COPD, and Respirato
Trial Acronym Year Exclusion Criteria
MDC 1993 Obstructive lung disease requiring beta2-agonists
CIBIS I 1994 Asthma
U.S. Carvedilol
Trials
1996 Any condition limiting exercise or survival, such as p
MOCHA 1996 Obstructive pulmonary disease requiring oral bronc
steroid therapy
PRECISE 1996 Any condition limiting exercise or survival, such as p
ANZ-Carvedilol 1997 Chronic obstructive airways disease, or current trea
CIBIS II 1999 Reversible obstructive lung disease
MERIT-HF 1999 Contraindication to beta-blockade
RESOLVD 2000 Chronic reversible airways disease requiring therapy
BEST 2001 Contraindication to beta-blockade, or beta-agonists
COPERNICUS 2001 Severe primary pulmonary disease, or contraindicat
therapy
CAPRICORN 2001 Significant pulmonary impairment, or therapy with
beta2-agonists or steroids
COMET 2003 History of asthma or chronic obstructive pulmonary
CIBIS III 2004 Obstructive lung disease contraindicating bisoprolol
SENIORS 2005 Regular inhaled bronchodilators, or history of bronc
ANZ-Carvedilol  Australia–New Zealand Heart Failure Research Collaborative Group Carvedilol
Controlled Evaluation; CIBIS  The Cardiac Insufficiency Bisoprolol Study; COMET  Carvedilol or
Prospective Randomized Cumulative Survival Study; MDC  Metoprolol in Dilated Cardiomyopath
Multicenter Oral Carvedilol Heart Failure Assessment trial; PRECISE  Prospective Randomized E
Left Ventricular Dysfunction Pilot; SENIORS  Study of Effects of Nebivolol Intervention on Outcomeported. Most recently, a randomized, open-label, sriple-crossover trial examined 35 patients with coexis-
ent COPD according to GOLD (Global Initiative for
hronic Obstructive Lung Disease) criteria (68). FEV1
was significantly lower with carvedilol (1.85 l/s) than
with metoprolol (1.94 l/s) and bisoprolol (2.00 l/s). To
conclude, there are no robust data supporting the safety
or efficacy of carvedilol, particularly in patients with
moderate to severe or reversible airways disease.
Effect of Beta-Blockade on
Mortality in Patients With HF and COPD
In observational studies, use of beta-blockers is consistently
associated with better survival in patients with HF and
concurrent COPD (46,69,70), a finding corroborated in
post–myocardial infarction populations (29,71). In the Val-
HeFT (Valsartan Heart Failure Trial) (46), 140 (22%) of
628 participants with physician-recorded COPD received
beta-blockers. Mortality over a mean of 23 months was
approximately 17%, as opposed to 31% in those with HF
and COPD not prescribed beta-blockers (p  0.001). The
ALIANT (Valsartan in Acute Myocardial Infarction
rial) enrolled patients with myocardial infarction compli-
ated by HF, LVSD, or both. A higher proportion of the
,258 patients with concurrent COPD received beta-
lockers (51%), with an associated lower mortality (25% vs.
5%, p  0.001) (70). Finally, a retrospective Canadian
ajor Beta-Blocker Trialsmptoms in Major Beta-Blocker Trials
Prevalence
Of COPD
Beta-
Blocker
Respiratory
Symptoms
(Beta-Blocker vs.
Placebo)
Not reported Metoprolol Not reported
Not reported Bisoprolol Not reported
ary disease Not reported Carvedilol Cough 8% vs. 10%
or or Not reported Carvedilol Respiratory disorder
5% vs. 11%
ary disease Not reported Carvedilol Not reported
with a beta-agonist Not reported Carvedilol Not reported
Not reported Bisoprolol Not reported
5.3% Metoprolol Not reported
Not reported Metoprolol Not reported
Not reported Bucindolol Not reported
beta-blocker Not reported Carvedilol Not reported
Not reported Carvedilol Not reported
e Not reported Carvedilol,
metoprolol
Not reported
ent Not reported Bisoprolol Not reported
m or asthma Not reported Nebivolol Not reported
EST  Beta-Blocker Evaluation of Survival Trial; CAPRICORN  Carvedilol Post-Infarct Survival
rolol European Trial; COPD  chronic obstructive pulmonary disease; COPERNICUS  Carvedilol
IT-HF  Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure; MOCHA 
n of Carvedilol on Symptoms and Exercise; RESOLVD  Randomized Evaluation of Strategies for
d Rehospitalization in Seniors With Heart Failure.in Mry Sy
ulmon
hodilat
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who were prescribed beta-blockers, after comprehensive
adjustment for age, sex, comorbidity, and propensity scores
(hazard ratio: 0.78, 95% confidence interval: 0.63 to 0.95).
None of the studies assessed pulmonary function, limiting
inference to patients with severe or reversible airflow ob-
struction. Prescribing bias is inevitable due to perceived or
documented intolerance to beta-blockers. This is com-
pounded by recruitment bias in analyses from clinical trials,
whose enrolment criteria often excluded patients with sig-
nificant pulmonary disease. The lower mortality of patients
receiving beta-blockers may well reflect less severe lung
disease.
Physiological Rationale
for Adverse Beta2-Agonist Effects
Reduced organ perfusion in HF results in a compensatory
increase in adrenergic drive. Epinephrine and norepineph-
rine stimulate ventricular contraction and increase vascular
resistance, maintaining cardiac output and blood pressure.
Longer term, increased mechanical stress, myocardial oxy-
gen demand, and ischemia combine with maladaptive ad-
renergic signaling to depress myocardial function. Beta1-
and beta2-adrenoceptors mediate norepinephrine toxicity,
fibrosis, and necrosis. Down-regulation of beta1-receptors
with relative preservation of the beta2 subpopulation reduces
the beta1/beta2 ratio (72). The chronotropic and inotropic
Association Between Beta-Agonists and HFTable 4 Association Between Beta-Agonists and HF
First Author (Ref. #) Population Route Bronchodil
Martin et al. (43) Asthma Oral Bambuterol
Inhaled Salmeterol
Coughlin et al. (44) General
population
Oral Beta-agonist
Inhaled nebulized Beta-agonist
Sengstock et al. (38) Cardiology clinic Inhaled Beta-agonist
Macie et al. (87) COPD or asthma Inhaled Beta-agonist
Au et al. (37) HF Inhaled Beta-agonist
General medical
clinics
Inhaled Beta-agonist
Au et al. (36) LVSD Inhaled Beta-agonist
Singer et al. (101) Acute HF
without COPD
Inhaled Any bronchod
CI  confidence interval; DCM  idiopathic dilated cardiomyopathy; HF  heart failure; LVSD  leesponsiveness (and likewise vulnerability) of the failingyocardium to beta2-agonists thereby assumes greater im-
ortance (73,74).
Beta2-agonists exert numerous unfavorable cardiovascular
effects: tachycardia, hypokalemia, QTC prolongation, pe-
ripheral vasodilation, disturbed autonomic modulation, and
depressed heart rate variability (75–78). In susceptible
patients, beta2-agonists may precipitate ischemic events
(79,80). Hypoxia, hypercapnia, acidosis, and excess sympa-
thetic activity in pulmonary disease all potentially amplify
these sequelae (75,81,82). When combined with the ar-
rhythmic substrate of left ventricular dysfunction (83), the
risk of life-threatening arrhythmias cannot be discounted.
However, theoretical concerns may be misplaced. Although
beta2-agonists may exacerbate hypokalemia associated with
diuretics (84), hyperkalemia induced by intensive renin
angiotensin inhibition may conversely be reduced. Research
is needed to define the overall influence of beta-agonists in
contemporary populations.
Cautions Regarding the Adverse Associations
Between Beta-Agonists and HF
Beta-agonists are associated with incident HF in patients
with pulmonary disease, and with increased mortality and
HF hospitalization in those with existing HF or LVSD
(Table 4). These reported adverse associations merit careful
scrutiny. The evidence was derived from retrospective co-
hort or case control analyses, all of which equated drug
Study
Design N Outcome
Risk Associated
With Bronchodilator Use
(95% CI)
Cohort 8,098 HF RR: 3.41 (1.99–5.86),
p  0.0001
Cohort 15,407 HF RR: 1.10 (0.63–1.91),
p  0.7
Case control 387 DCM OR: 3.4 (1.1–11.0)
Case control 387 DCM OR: 3.2 (1.4–7.1)
Case control 190 DCM OR: 1.0
Case control 59,336 HF hospitalization OR: 1.74 (1.60–1.91)
Case control 1,121 HF hospitalization OR: 1.5 (0.8–2.8),
1–2 canisters
OR: 2.1 (1.0–4.3),
3 canisters
Case control 13,012 HF hospitalization OR: 1.3 (0.9–1.8),
1–2 canisters
OR: 1.1 (0.8–1.6),
3 canisters
Cohort 1,529 Death RR: 0.9 (0.5–1.6),
1 canister/month
RR: 1.4 (0.9–2.2),
2 canisters/month
RR: 2.0 (1.3–3.2),
3 canisters/month
Cohort 7,299 Death IV
Vasodilator use
Ventilation
OR: 1.02 (0.67–1.56)
OR: 1.40 (1.18–1.67)
OR: 1.69 (1.21–2.37)
icular systolic dysfunction; OR  odds ratio; RR  relative risk; other abbreviations as in Table 2.ator
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2) confounding by collinear pulmonary disease; and 3) bias
by indication. Multivariable analyses are often restricted in
epidemiological studies due to residual confounding by
unmeasured covariates. Cardiovascular risk factors and dis-
eases both cluster in patients with COPD, along with
underuse of beta-blockers (70,85).
Pulmonary disease may cause cardiac injury through
hypoxia, arrhythmias, or even atherosclerotic mechanisms
(86). The poor outcomes attributed to beta-agonists may
reflect the disease for which they are prescribed. Separating
the two is difficult. Dose-response relationships are limited
without adjustment for severity of airflow obstruction and
cumulative smoking burden (36,80). Patients using more
bronchodilators may simply have more severe pulmonary
disease. Both physician- and patient-mediated confounding
by indication is unavoidable. Physicians may mistakenly
prescribe beta-agonists or patients may increase beta-
agonist use for symptoms of HF.
Beta-Agonists and Incident HF
Five reports have addressed the association between beta-
agonists and incident HF in the general population or those
with pulmonary disease (37,38,43,44,87). Prescription event
monitoring collates physician reports of adverse events
associated with newly launched drugs. Oral bambuterol, but
not inhaled salmeterol, was associated with an increased
incidence of HF in 8,098 patients when compared with the
reference drug nedocromil (risk ratio: 3.41 [95% CI: 1.99 to
5.86], p  0.001) (43). However, the bambuterol cohort
received fewer prescriptions for asthma (57.3% vs. 70.2%)
and more “other” indications (12.8% vs. 2.8%). Therefore,
bambuterol may have unmasked previously undiagnosed
HF, as suggested by the greater risk in the first month of
exposure compared with months 2 to 6 (respectively, risk
ratio: 4.41 [95% CI: 1.90 to 10.27] vs. 2.67 [95% CI: 1.30
to 5.47]).
Two case-control studies assessed the risk of idiopathic
dilated cardiomyopathy defined by echocardiography asso-
ciated with beta-agonists (38,44). Numbers of events were
limited, resulting in wide confidence intervals and statistical
uncertainty. Both suffered the inherent failings of case
control methodology (88). In Washington, DC, oral beta-
agonists were associated with a 3-fold increased risk in 387
patients compared with community-based controls selected
using random digit dialing (odds ratio [OR]: 3.4, 95% CI:
1.1 to 11.0) (44). By contrast, a Detroit study (38) of 197
patients observed no significant relationship with inhaled
beta-agonists, employing clinic-based controls with isch-
emic cardiomyopathy. Although differences between oral
and inhaled administration are possible, the disparity most
likely relates to choice of control groups.
Two nested case-control studies yielded equally conflict-
ing results (37,87). The multicenter ACQUIP (Ambulatory
Care Quality Improvement Project) (37) examined health- ocare records from general medical clinics. Among 782
subjects hospitalized with HF, risk of admission was not
related to inhaled beta-agonists after adjusting for age,
cardiovascular comorbidity, beta-blocker prescription, and
presence of COPD (OR: 1.3, 95% CI: 0.9 to 1.8). By
contrast, the adjusted 1-year risk of HF hospitalization was
increased among patients with COPD or asthma who were
prescribed beta-agonists selected from the Manitoba Health
database (OR: 1.74, 95% CI: 1.60 to 1.91) (87). Therefore,
whether inhaled beta-agonists are implicated in the devel-
opment of HF remains uncertain.
Oral Beta-Agonists in HF
Numerous small, short-term controlled studies have exam-
ined the oral beta-agonists pirbuterol, prenalterol, salbuta-
mol, and terbutaline in patients with HF (89). The majority
demonstrated acute hemodynamic improvements, including
ejection fraction, cardiac index, and pulmonary capillary
wedge pressure (42). Although uncommon, ventricular
arrhythmias were reported (39). Only 2 studies recruited at
least 20 patients and lasted longer than a month (35,42).
Although symptoms and exercise tolerance improved, no
beta-agonist produced a sustained improvement in systolic
function. The trials lacked statistical power and were of
insufficient duration to identify longer-term impairment of
systolic performance.
The risk of arrhythmias is likewise uncertain. Oral
sympathomimetic drugs were associated with an increased
risk of arrhythmic hospitalization in a case-control study
examining 298 patients previously hospitalized with HF
(OR: 15.7, 95% CI: 1.1 to 228.0) (45). The confidence
intervals were unfortunately wide given the low absolute
number of patients receiving systemic sympathomimetics
(n  6). More importantly, the study failed to address the
isk of sudden death outside the hospital.
Two large, randomized controlled trials investigated oral
amoterol, a partial beta1-agonist. The first (33) random-
zed 433 patients with mild to moderate HF to receive
amoterol, digoxin, or placebo. Xamoterol improved exer-
ise capacity, dyspnea, and fatigue. The Xamoterol in Severe
eart Failure Study aimed to extend these findings in 516
atients with New York Heart Association functional class
II and IV symptoms. However, the trial was terminated
rematurely due to excess mortality in the xamoterol group
ithin 100 days of randomization (9.1% vs. 3.6%, p 0.02)
34). Both sudden death and progressive pump failure
ontributed to the increased mortality.
Respiratory guidelines favor inhaled over oral bronchodi-
ators due to rapid therapeutic action, greater efficacy, and
ewer side effects (2). However, neither cardiologic nor
ulmonary societies specifically counsel against oral agents
n patients with cardiovascular disease (1,2,48,90). This lack
f guidance is concerning. In the Val-HeFT, 73% of
atients with HF and concurrent COPD were prescribed
ral beta2-agonists (46).
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Nebulized doses are typically 10 greater than standard
inhalers. Two facts should be considered. Systemic adverse
effects are dose-dependent (91,92), and pulmonary absorp-
tion delivers beta-agonists to the heart without first-pass
metabolism. Nebulized beta-agonists may precipitate ar-
rhythmias and myocardial ischemia (93,94). Four acute
studies recruiting 44 patients in total have administered
nebulized beta2-agonists to patients with HF (30,32,41,95).
o adverse events were reported. In 13 patients, cardiac
utput and ejection fraction significantly increased within
0 min of inhalation, returning to baseline after 30 min
41). The remaining 3 studies observed a reduction in
irflow obstruction following nebulized salbutamol, but no
onsistent improvement in exercise capacity (30,32,95).
iven the limited patient numbers, clinical judgment is
aramount. Increasing from 2.5 to 5 mg salbutamol pro-
uces only limited incremental bronchodilation (96,97).
nhaled Beta-Agonists in HF
tandard metered-dose beta-agonist inhalers produce only
inor systemic and biochemical abnormalities (91,92,98).
hether these contribute to adverse events in patients with
F or LVSD is debatable (36,37). Among 1,529 patients
ith LVSD identified retrospectively through imaging re-
ords (36), all-cause mortality and HF hospitalization
ithin 1 year were associated with beta-agonist use. The
isk increased with the average number of canisters dis-
ensed per month. The respective adjusted hazard ratios
ere: 0.9 and 1.3 (1 canister/month); 1.4 and 1.7 (2
anisters/month); 2.0 and 2.0 (3 canisters/month). How-
ver, any association is undermined by the indication for
eta-agonist use: Increasing dyspnea and resulting beta-
gonist prescription may simply reflect worsening HF.
ithout markers of HF severity, the multivariate model
as unable to adjust for such confounding.
In the ACQUIP case-control study (37), beta-agonists
ere associated with HF hospitalization among those with
xisting HF (OR: 1.8, 95% CI: 1.1 to 3.0). Adjustment for
ge, cardiovascular comorbidity, beta-blocker prescription,
resence of COPD, and a marker of disease severity (steroid
se) reduced the magnitude of association (OR: 1.6, 95%
I: 1.0 to 2.7). Adding smoking status and pack-year
istory to the multivariate model rendered the relationship
onsignificant (OR: 1.5, 95% CI: 0.8 to 2.8). The findings
einforce concerns that the purported adverse effects of
eta-agonists relate to underlying pulmonary disease and
lustering of cardiovascular risk factors.
A single study has prospectively investigated inhaled
eta-agonists, administering salmeterol 84 g twice daily to
8 patients with New York Heart Association functional
class II or III HF (31). Compared with placebo, salmeterol
use improved FEV1 by 6% (p 0.01). Concomitant airflow
bstruction limits interpretation: mild COPD was notxcluded; baseline FEV1 was reduced in all patients; and
smoking history was not documented. The pharmacokinetic
data proved more revealing. The steady-state trough and
peak concentrations and half-life of salmeterol were at least
double those reported in patients with asthma. Physicians
must be wary of diminished beta-agonist hepatic metabo-
lism in patients with HF.
Beta-Agonists in Acute HF
Inhaled beta-agonists have never been prospectively evalu-
ated in patients with decompensated HF, although the
physiological actions are appealing: enhanced cardiac out-
put, reduced peripheral vascular resistance, and bronchodi-
lation (99). However, numerous clinical trials have tested
therapies with favorable hemodynamic activity in patients
with acute HF, none of which improved mortality (1).
Analogies with intravenous inotropic drugs acting through
adrenergic pathways are inescapable. Acute improvement
may belie myocardial injury leading to increased mortality
(1,100). Evidence from 7,299 patients without COPD
enrolled in the Acute Decompensated Heart Failure Na-
tional Registry supports these concerns (101). Bronchodi-
lators were administered to 14.3% of patients and associated
with greater requirement for intravenous vasodilators (ad-
justed OR: 1.40, 95% CI: 1.18 to 1.67) and mechanical
ventilation (OR: 1.69, 95% CI: 1.21 to 2.37). Hospital
mortality was similar regardless of bronchodilator therapy.
Interaction Between
Beta-Blockers and Beta-Agonists
The unequivocal pharmacological interaction between beta-
blockers and beta-agonists is likely to influence clinical
effectiveness. Nevertheless, the evidence supporting an in-
teraction is circumstantial and derives largely from patients
experiencing myocardial infarction. The effects of beta-
blockers may be attenuated by beta-agonists. Less benefit
was apparent in clinical trials using beta-blockers with
intrinsic sympathomimetic activity after infarction (102).
Beta-blocker use was also not associated with lower mor-
tality among patients receiving concurrent beta-agonists in
the Cooperative Cardiovascular Project (29). Conversely,
the effects of beta-agonists, both adverse and beneficial, may
be attenuated by beta-blockers. The risk of acute coronary
syndromes associated with beta-agonists was lessened by
concurrent beta-blockade in a case-control study using data
from the Veterans Administration’s ACQUIP trial (p for
interaction 0.0005) (80). The aforementioned interaction
between beta-blockers and beta-agonist bronchodilator re-
sponse must also be considered. Whereas cardioselective
beta-blockers permit bronchodilation, noncardioselective
beta-blockers inhibit beta-agonist response.
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Beta-blockers. The uncertainty arising from the paucity of
evidence must be balanced against 1 certainty: Beta-blockers
markedly improve symptoms and survival in patients with
HF. Patients should not be denied therapy that reduces
mortality by 35% (66,103,104). COPD (even moderate or
severe) is not a contraindication to beta-blockers. Low-dose
initiation and gradual up-titration is recommended. Car-
dioselectivity is paramount; metoprolol, bisoprolol, and
nebivolol are candidates.
Beta-agonists. Beta-agonists are associated with increased
mortality and hospitalization in patients with HF, and they
fail to improve hard clinical endpoints in patients with
COPD. Clinicians should only prescribe beta-agonists for
clear symptom relief, after carefully considering the etiology
of dyspnea and objectively documenting airflow obstruction.
Oral beta-agonists should be avoided, and both the dose and
frequency of nebulized therapy should be minimized. The
possibility of worsening HF must always be considered
when beta-agonist use increases in patients with HF and
concurrent COPD.
Just as COPD and HF frequently coexist (4), so too do
COPD and asthma. Even though randomized controlled
trials have established the safety of long-acting beta-
agonists in patients with COPD (105), concerns remain
regarding safety in patients with asthma that have necessi-
tated label changes under the Food and Drug Administra-
tion Amendments Act (106). No prospective study has
addressed the safety of long-acting beta-agonists in patients
with COPD and concomitant asthma. By contrast, the
long-acting anticholinergic bronchodilator tiotropium has
proven efficacy in both COPD and more recently asthma
(107,108), with reassuring cardiovascular safety data and
U.S. Food and Drug Administration approval (109,110).
Moreover, another recent large randomized controlled trial
has shown tiotropium to be more effective than and equally
as safe as salmeterol in patients with COPD (111). Patients
with HF and concomitant COPD who require regular
long-acting inhaled bronchodilators, therefore, should start
treatment with a long-acting antimuscarinic rather than
long-acting beta-agonists.
Conclusions
The combination of HF and COPD presents complex
therapeutic challenges. Many questions remain unanswered.
The efficacy of beta-blockade in patients with mild and fixed
airflow obstruction likely extends to those with more severe
disease, though the evidence is rudimentary. The long-term
influence of beta-blockade on pulmonary function, symp-
toms, and quality of life is unclear. Robust clinical trials are
required to provide the answers that may finally allay
physicians’ mistrust of beta-blockers in patients with
COPD. The potential adverse effects of beta-agonists like-
wise require further clarification. Studies should be random-ized, placebo-controlled, and of sufficient magnitude to
investigate clinical outcomes. The U.S. Food and Drug
Administration recently convened to consider the safety of
long-acting beta-agonists in asthma (106). The safety of
beta-agonists in patients with HF and concurrent pulmo-
nary disease appears equally concerning.
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